• Home
  • Search Results
  • Inhibition of platelet functions and thrombosis through selective or nonselective inhibition of the platelet P2 receptors with increasing doses of NF449 [4,4',4'',4'''-(carbonylbis(imino-5,1,3-benzenetriylbis-(carbonylimino)))tetrakis-benzene-1,3-disulfonic acid octasodium salt].

Inhibition of platelet functions and thrombosis through selective or nonselective inhibition of the platelet P2 receptors with increasing doses of NF449 [4,4',4'',4'''-(carbonylbis(imino-5,1,3-benzenetriylbis-(carbonylimino)))tetrakis-benzene-1,3-disulfonic acid octasodium salt].

The Journal of pharmacology and experimental therapeutics (2005-03-29)
Béatrice Hechler, Stéphanie Magnenat, Maddalena L Zighetti, Matthias U Kassack, Heiko Ullmann, Jean-Pierre Cazenave, Richard Evans, Marco Cattaneo, Christian Gachet
ABSTRACT

Our aim was to determine whether the newly described P2X1 antagonist NF449 [4,4',4'',4'''-(carbonylbis(imino-5,1,3-benzenetriylbis(carbonylimino)))tetrakis-benzene-1,3-disulfonic acid octasodium salt] could selectively antagonize the platelet P2X1 receptor and how it affected platelet function. NF449 inhibited alpha,beta-methyleneadenosine 5'-triphosphate-induced shape change (IC50 = 83 +/- 13 nM; n = 3) and calcium influx (pA2 = 7.2 +/- 0.1; n = 3) (pIC50 = 6.95) in washed human platelets treated with apyrase to prevent desensitization of the P2X1 receptor. NF449 also antagonized the calcium rise mediated by the P2Y1 receptor, but with lower potency (IC50 = 5.8 +/- 2.2 microM; n = 3). In contrast, it was a very weak antagonist of the P2Y12-mediated inhibition of adenylyl cyclase activity. Selective blockade of the P2X1 receptor with NF449 led to reduced collagen-induced aggregation, confirming a role of this receptor in platelet activation induced by collagen. Intravenous injection of 10 mg/kg NF449 into mice resulted in selective inhibition of the P2X1 receptor and decreased intravascular platelet aggregation in a model of systemic thromboembolism (35 +/- 4 versus 51 +/- 3%) (P = 0.0061; n = 10) but without prolongation of the bleeding time (106 +/- 16 versus 78 +/- 7 s; n = 10) (N.S.; P = 0.1209). At a higher dose (50 mg/kg), NF449 inhibited the three platelet P2 receptors. This led to a further reduction in platelet consumption compared with mice injected with saline (13 +/- 4 versus 42 +/- 3%) (P = 0.0002; n = 5). NF449 also reduced dose-dependently the size of thrombi formed after laser-induced injury of mesenteric arterioles. Overall, our results indicate that NF449 constitutes a new tool to investigate the functions of the P2X1 receptor and could be a starting compound in the search for new antithrombotic drugs targeting the platelet P2 receptors.

MATERIALS
Product Number
Brand
Product Description

Supelco
Benzyl alcohol, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Benzyl alcohol, anhydrous, 99.8%
Sigma-Aldrich
Benzyl alcohol, ReagentPlus®, ≥99%
Sigma-Aldrich
Benzyl alcohol, ACS reagent, ≥99.0%
Supelco
Benzyl alcohol, analytical standard
Sigma-Aldrich
Benzyl alcohol, natural, ≥98%, FG
Sigma-Aldrich
Benzyl alcohol, puriss., meets analytical specification of Ph. Eur., BP, NF, 99-100.5% (GC)
Sigma-Aldrich
Benzyl alcohol, ≥99%, FCC, FG
Sigma-Aldrich
Benzyl alcohol, puriss. p.a., ACS reagent, ≥99.0% (GC)
Benzyl alcohol, European Pharmacopoeia (EP) Reference Standard
Supelco
Benzyl alcohol, certified reference material, TraceCERT®
Supelco
Benzyl alcohol solution, certified reference material, 2000 μg/mL in methylene chloride